Tip 1 Diyabetli Çocuk ve Adölesanların İnsülin Pompa Yönetiminde Sorunlar ve Çözüm Önerileri

Abstract

Tip 1 Diyabet, diyabetli çocuk ve ebeveynlerinin tanı anından itibaren yaşam boyunca sürdürmeleri gereken tekrarlı eğitim, özen ve yakın takip ile yönetebilecekleri bir süreçtir. Tip 1 diyabet yönetim bileşenlerini insülin tedavisi, sağlıklı beslenme, fiziksel aktivite, kendi kendine izlem, multidisipliner yakın takip ve hemşirelik yaklaşımı oluşturur. Bu bileşenlerin merkezinde insülin tedavisi yer almaktadır. Diyabet teknolojilerinin gelişimi ile diyabetli çocuk ve ebeveynlerinin yaşamına sürekli insülin gönderimini otomatik olarak yapan elektromekanik bir pompa girmiştir. Bu derleme makalesinde küresel anlamda kullanımı oldukça yaygınlaşan insülin infüzyon pompasının avantaj ve dezavantajları literatür ışığında detaylı bir biçimde ele alınmıştır

Keywords

• Tip 1 diyabetes mellitus
• insülin infüzyon pompa
• çocuk
• adolesan

Problems in Insulin Pump Management and Suggestions for Solutions in Children and Adolescents with Type 1 Diabetes

Abstract

Type 1 diabetes is a process that children with diabetes and their parents can manage through repetitive training, care and close monitoring that they need to continue throughout their lives at the time of diagnosis. Type 1 forms diabetes management components into insulin treatment, healthy nutrition, physical activity, self-monitoring, multidisciplinary close-up and nursing approach. Insulintherapy is central to these components. With the development of diabetes technologies, an electromechanical pump entered the lives of the diabetic child and his or her parents, who automatically sends insulin continuously.In this compilation article, the advantages and disadvantages of the insulin infusion pump, which has become widely used globally, have been discussed in detail in the literature.

Keywords

• Type 1 diabetes mellitus
• Insulin infusion pump
• Child
• Adolescent

References

1. 1. Baştopçu Ö, Arslan S, Arslanoğlu İ. Tip 1 diyabetli adölesanların uyku ve yaşam kalitesi ile psikolojik sağlamlık düzeyleri arasındaki ilişki. IAAOJ Health Sciences. 2021; 7(2): 56-78.
2. 2. https://diabetesatlas.org/idfawp/resourcefiles/2021/07/IDF_Atlas_10th_Edition_2021.pdf Erişim Tarihi: 27. 02. 2022.
3. 3. Güven M, Anık A, Ünüvar T, Şendur N. Tip 1 diabetes mellituslu çocuk hastalarda deri bulguları. Turkderm -Turk Arch Dermatol Venereol. 2020; 55:22-6.
4. 4. Yeşilkaya E, Cinaz P, Andıran N, Bideci A, Hatun Ş, Sarı E, Türker T, Akgül Ö, Saldır M, Kılıçaslan H, Açıkel C, Craig ME. First report on the nationwide incidence and prevalence of type 1 diabetes among children in Turkey. Diabetic Medicine. 2016; 34(3):405-410.
5. 5. Delibaş L, Erci B. Sosyal bilişsel kuram temelli eğitimle tip 1 diyabetli çocukların hastalık yönetiminin desteklenmesi. TJFMPC. 2021;15(2): 404-413.
6. 6. Lang EG, King BR, Miller MN, Dunn SV, Price DA, Foskett DC. Initiation of insulin pump therapy in children at diagnosis of type 1 diabetes resulted in improved long‐term glycemic control. Pediatric diabetes. 2017;18(1): 26-32.
7. 7. Lechleitner M, Kaser S, Hoppichler F, Roden M, Weitgasser R, Ludvik B, Fasching P, Winhofer-Stöckl Y, Kautzky-Willer A, Schernthaner G, Prager R, C.Wascher T, Clodi M. Diagnostik und therapie des typ 1 diabetes mellitus. Wien Klin Wochenschr. 2019; 131: 77–84.
8. 8. Civil T, Gündüz N, Ersöz G, Koz M, Emeksiz HC, Gören Atalay N. 6-17 yaş tip 1 diyabetli hastaların fiziksel ve sportif aktivitelere katılımlarının birtakım değişkenler açısından incelenmesi. Hacettepe University Faculty of Health Sciences Journal. 2019; 6 (2):139-150.

9. 9. Ziegler R, Neu A. Diabetes in childhood and adolescence. Deutsches Ärzteblatt International Dtsch Arztebl Int. 2018; 115: 146–56.
10. 10. Malik FS, Taplin CE. Insulin therapy in children and adolescents with type 1 diabetes. Pediatr Drugs. 2014;16: 141–150. 11. Weinzimer SA, Swan KL, Sikes KA, Ahern JH. Emerging evidence fort he use of insülin pump therapy in infants, toodlers and preschool-aged children with type 1 diabetes. Pediatric Diabetes. 2006;7(4):15-19.
11. 12. Nimri R, Nir J, Phillip M. Insulin pump therapy. American journal of therapeutics. 2020; 27(1):30-41
12. 13. Ziegler R, Waldenmaier D, Kamecke U, Mende J, Haug C, Freckman G. Accuracy assessment of bolus and basal rate delivery of different insulin pump systems used in insulin pump therapy of children and adolescents. Pediatric Diabetes.2020; 21:649–656.
13. 14. Traill C, Halpern SH. Insulin Pump. In: Mankowitz S. (eds) Consults in Obstetric Anesthesiology. Springer, Cham, 2018, 319-321.
14. 15. Sherr JL,Tauschmann M, Battelino T, de Bock M, Forlenza G, Roman R, Hood K, Maahs DM. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes Technologies. Pediatric Diabetes October. 2018; 19 (27): 302–325.
15. 16. Auzanneau M, Karges B, Neu A, Kapellen T, Wudy, SA, Grasemann C, Krauch G, Gerstl EM, Daüblin G, Holl RW. Use of insulin pump therapy is associated with reduced hospital-days in the long-term: a real-world study of 48,756 pediatric patients with type 1 diabetes. European Journal of Pediatrics. 2020; 180(2): 597-606.
16. 17. Şahinol M, Başkavak G. Sosyo-Biyo-Teknik bakım kompleksi: tip 1 diyabette dijital sağlık takibi. Sosyoloji Araştırmaları Dergisi/Journal Of Sociological Research. 2021; Özel Sayı: 110-145.
17. 18. Mueller‐Godeffroy E, Vonthein R, Ludwig‐Seibold C, Heidtmann B, Boettcher C, Kramer M, Hessler N, Hilgard D, Lilienthal E, Zeigler A, M. Wagner V, German Working Group for Pediatric Pump Therapy (agip). Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: the pumpkin multicenter randomized controlled trial. Pediatric diabetes.2018;19(8): 1471-1480.
18. 19. Addala A, Auzanneau M, Miller K, Maier W, Foster N, Kapellen T, Walker A, Rosenbauer J, Maahs DM, Holl RW. A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: A Transatlantic Comparison. Diabetes Care. 2020;44: 133–140.
19. 20. van den Boom L, Karges B, Auzanneau M, Rami-Merhar B, Lilienthal E, von Sengbusch S, Datz N, Schröder C, Kapellen T, Laimer M, Schmid SM, Müller H, Wolf J, Holl RW. Temporal trends and contemporary use of ınsulin pump therapy and glucose monitoring among children, adolescents, and adults with type 1 diabetes between 1995 and 2017. Diabetes Care. 2019; 42(11): 2050 2056.
20. 21. Cardona-Hernandez R, Schwandt A, Alkandri H, Bratke H, Chobat A, Coles N, Corathers S, Goksen D, Gross P, İmane Z, Nagl K, Riordan SMO, Jefferies C. Glycemic outcome associated with ınsulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the ınternational pediatric registry SWEET. Diabetes Care. 2021;44(5):1176–1184.
21. 22. Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U, Boettcher C, Kapellen T, Rosenbauer J, Holl RW. Association of ınsulin pump therapy vs ınsulin ınjection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA. 2017; 318(14): 1358-1366.
22. 23. Hussain T, Akle M, Nagelkerke N, Deeb A. Comparative study on treatment satisfaction and health perception in children and adolescents with type 1 diabetes mellitus on multiple daily injection of insulin, insulin pump and sensor-augmented pump therapy. SAGE Open Medicine. 2017;5: 2050312117694938.
23. 24. Mavinkurve M, Quinn A, O'Gorman. Continuous subcutaneous insulin infusion therapy for Type 1 diabetes mellitus in children. Ir J Med Sci. 2016; 185, 335–340.
24. 25. Pickup JC. Is insulin pump therapy effective in Type 1 diabetes? Diabetic Medicine.2019;36(3): 269-278.
25. 26. Fredheim S, Johansen A, Thorsen SU, Kremke B, Nielsen LB, Olsen BS, Lyngsøe L, Sildorf SM, Pipper C, Mortensen HB, Johannesen J, Svensson J. Danish Society for Diabetes in Childhood and Adolescence. Nationwide reduction in the frequency of severe hypoglycemia by half. Acta Diabetol. 2015; 52(3): 591- 599.
26. 27. Thabit H, Hovorka R. Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. Expert Opin Drug Deliv. 2016; 13(3): 389- 400.
27. 28. Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2016; 32(1): 21- 39.
28. 29. Brorsson AL, Viklund G, Örtqvist E, Lindholm Olinder A. Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? A retrospective case–control study. Pediatrik Diyabet. 2015; 16 (7): 546-553. 30. Wadwa RP, Fiallo-Scharer R, Vanderwel B, Messer LH, Cobry E, Chase HP. Continuous glucose monitoring in youth with type 1 diabetes. Diabetes Technol Ther. 2009; 11(1): 83- 91.
29. 31. Berget C, Messer LH, Forlenza GP. A clinical overview of insulin pump therapy for the management of diabetes: past, present, and future of intensive therapy. Diabetes Spectrum. 2019;32(3): 194-204.
30. 32. Qin Y, Yang LH, Huang XL, Chen XH. Efficacy and safety of continuous subcutaneous insulin infusion vs. multiple daily injections on type 1 diabetes children: a meta-analysis of randomized control trials. J Clin Res Pediatr Endocrinol. 2018; 10(4): 316- 323.
31. 33. Rankin D, Harden J, Noyes K, Waugh N, Barnard K, Lawton J. Parents' experiences of managing their child's diabetes using an insulin pump: a qualitative study. Diabetic medicine. 2015; 32(5): 627-634.
32. 34. Birkebaek NH, Kristensen LJ, Mose AH, Thastum M, Danish Society for Diabetes in Childhood and Adolescence. Quality of life in Danish children and adolescents with type 1 diabetes treated with continuous subcutaneous insulin infusion or multiple daily injections. Diabetes research and clinical practice. 2014;106(3): 474-480.
33. 35. Al Shaikh A, Al Zahrani AM, Qari, YH, Abu Alnasr AA, Alhawsawi WK, Alshehri K A, Al Shaikh SA. Quality of life in children with diabetes treated with ınsulin pump compared with multiple daily ınjections in tertiary care center. Clinical Medicine Insights: Endocrinology and Diabetes. 2020; 13:1-6 .
34. 36. Cemeroglu AP, Stone R, Kleis L, Racine MS, Postellon DC, Wood MA. Use of a real‐time continuous glucose monitoring system in children and young adults on insulin pump therapy: patients' and caregivers' perception of benefit. Pediatric diabetes. 2010; 11(3): 182-187.
35. 37. Conwell LS, Pope E, Artiles AM, Mohanta A, Daneman A, Daneman D. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. The Journal of pediatrics. 2008; 152(5): 622-628.
36. 38. Binder E, Lange O, Edlinger M, Meraner D, Abt D, Moser C, Hofer SE. Frequency of dermatological side effects of continuous subcutaneous insülin infusion in children and adolescents with type 1 diabetes. Experimental and Clinical Endocrinology & Diabetes. 2015; 123(04): 260-264.
37. 39. Al Hayek AA, Robert AA, Al Dawish MA. Skin-related complications among adolescents with type 1 diabetes using insulin pump therapy. Clinical Medicine Insights: Endocrinology and Diabetes. 2018; 11: 1179551418798794.
38. 40. Schober E, Rami B. Dermatological side effects and complications of continuous subcutaneous insulin infusion in preschool‐age and school‐age children. Pediatric Diabetes. 2009; 10(3):198-201.
39. 41. Ross P, Gray AR, Milburn J, Kumarasamy IM, Wu F, Farrand S, Wheeler BJ. Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type. Acta diabetologica. 2016; 53(6): 991-998.
40. 42. Messer LH, Berget C, Beatson C, Polsky S and Forlenza GP. Preserving skin ıntegrity with chronic device use in diabetes. Diabetes Technol Ther. 2018 ;20(2):254-264.
41. 43. Berg AK, Olsen BS, Thyssen JP, Zachariae C, Simonsen AB, Pilgaard K, Svensson J. High frequencies ofdermatological complications in children using insulinpumps or sensors. Pediatr Diabetes. 2018;19: 733–740.
42. 44. Demir G, Er E, Atik-Altınok Y, Özen S, Darcan Ş, Gökşen D. Local complications of insulin administration sites and effect on diabetes management. J Clin Nurs. 2021; 00:1–9.
43. 45. Moser EG, Morris AA, Garg SK. Emerging diabetes therapies and technologies. Diabetes Res Clin Pract. 2012; 97:16–26.
44. 46. Heinemann L, Fleming GA, Petrie JR, Holl RW, Bergenstal RM, Peters AL. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia.2015; 58(5):862-870.
45. 47. Ross PL, Milburn J, Reith DM, Wiltshire E, Wheeler BJ. Clinical review: insulin pump-associated adverse events in adults and children. Acta diabetologica. 2015; 52(6): 1017-1024.
46. 48. Lipman TH, Willi SM, Lai CW, Smith JA, Patil O, Hawkes CP. Insulin pump use in children with type 1 diabetes: over a decade of disparities. Journal of Pediatric Nursing. 2020; 55: 110-115.
47. 49. Urakami T, Habu M, Suzuki J. Diyabetic ketoasidozis and severe hypoglycemia in management of type 1 diabetes during 2003-2013. Pediatr Int. 2014; 56:940.
48. 50. Wheeler BJ, Donaghue KC, Heels K, Ambler GR. Family perceptions of insulin pump adverse events in children and adolescents. Diabetes Technology & Therapeutics. 2014;16(4): 204-207.
49. 51. Tsalikian E, Fox L, Weinzimer S, and the Diabetes Research in Children Network (DirecNet) Study Group. Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. Pediatr Diabetes. 2012;13(4):301-307.
50. 52. Englert K, Ruedy K, Coffey J, Caswell K, Steffen A, Levandoski L, Diabetes Research in Children (DirecNet). Study Group Skin and adhesiveissues with continuous glucose monitors: a sticky situation.J Diabetes Sci Technol. 2014; 8:745–751.
51. 53. Ives B, Sikes K, Urban A, Stephenson K, Tamborlane WV. Practical aspects of real-time continuous glucose monitors: the experience of the Yale Children’s Diabetes Program. Diabetes Educ. 2010; 36:53–62.
52. 54. McNichol L, Lund C, Rosen T, Gray M: Medical adhesivesand patient safety: State of the science: consensus statementsfor the assessment, prevention, and treatment of adhesive-related skin injuries. J Wound Ostomy Continence Nurs. 2013;40:365–380; quiz E361–E362.
53. 55. Bryant RA. Saving the skin from tape injuries. Am J Nurs.1988;88(2):189–191.
54. 56. Mahmud FH, Elbarbary NS, Fröhlich-Reiterer E, Holl RW, Kordonouri,O, Knip M, Simmons K, Craig, ME. ISPAD Clinical Practice Consensus Guidelines 2018: Other complications and associated conditions in children and adolescents with type 1 diabetes. Pediatric diabetes. 2018: 19(27); 275-286.
55. 57. Medtronic Diabetes: Tape Tips and Site Management. https://www.medtronicdiabetes.com/sites/default/files/library/download library/workbooks/Tape%20Tips%20and%20Site%20Management.pdf (Erişim 03.03.2022).
56. 58. Jarosz-Chobot P, Nowakowska M, Polanska J. Seeking the factors predisposing to local skin inflammatory state development in children with type 1 diabetes (T1DM) treated with continuous subcutaneous insulin infusion (CSII). Exp Clin Endocrinol Diabetes. 2007; 115(3):179-181.
57. 59. Jamal MA, Garoge K, Rosenblatt JS, Hachem RY, Raad II. Development of gendine-coated cannula for continuous subcutaneous insulin infusion for extended use. Antimicrob Agents Chemother. 2015;59(8): 4397-4402.
58. 60. Chase HP, Messer L: Understanding ınsulin pumps and continuous glucose monitors. 3rd ed. Denver: Children’s Diabetes Research Foundation, 2016.